|
Roche cuts Hepatitis C drug cost by 65% for government institutions
|
|
|
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/roche-cuts-hepatitis-c-drug-cost-by-65-for-government-institutions/articleshow/47647294.cms
NEW DELHI: Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in India.
After the price reduction, the medicine is now available at Rs 3,250 per pre-filled syringe plus taxes across all government institutions in the country, Roche said in a statement.
The move to reduce its cost of therapy is in line with Roche's commitment to treat patients with Hepatitis C, which continues to be a substantial disease burden in the northern states of India..., it added.
Exxura is available as a pre-filled syringe version to the patients, which offers dosing accuracy and convenience, the company said.
Commenting on the development, Director - Market Access for Roche India V Simpson Emmanuel said: "Roche is committed to working with the government and other stakeholders to control Hepatitis C infection..."
The company, quoting WHO, said 12 million people are chronically infected with Hepatitis C infection in India.
|
|
|
|
|
|
|